2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

2328 Let there be LIGHT: Molecular regulation of interleukin-7 production

Marco Rosichini, Paul Deroos2, Marialuigia Catanoso3, Franco Locatelli, MD PhD4, Enrico Velardi, PhD5, Jarrod Dudakov, MD, PhD6
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Bambino Gesu' Children Hospital, Rome, Italy
4 Bambino Gesu' Children Hospital, Rome, Italy, Catholic University of the Sacred Heart, Rome, Italy
5 Bambino Gesu' Children Hospital, Rome, Italy
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States

Hematopoietic cell transplantation (HCT) is a widely-used therapy for a variety of hematologic malignancies. However, the required conditioning regimen causes prolonged immunosuppression, especially of the T cell lineage, thus exposing patients to infections and disease relapse. These are leading causes of death in HCT recipients, therefore identifying new strategies to enhance T cell recovery represents an unmet clinical need. De novo T cell development relies on a set of reciprocal interactions between thymocytes and the thymic microenvironment, primarily thymic epithelial cells (TECs). Thymic crosstalk is also critical for thymic recovery after acute insult such as HCT conditioning. Notably, clinical observations suggest that donor lymphocytes infusion (DLI) in HCT recipients promotes increased levels of IL-7 in serum and faster thymic recovery, suggesting that lymphocytes subsets are involved in IL-7 regulation.

We established a primary culture of human TECs. Co-culture with DLI bags leftovers or healthy donor-derived lymphocytes resulted in upregulation of IL-7. To determine the cellular regulator of this process, lymphocyte subsets were isolated and co-cultured with TECs, revealing that Mucosal Associated Invariant T (MAIT) cells were the primary cellular mediators of IL-7 regulation, notably independently of physical interaction. Coherently, MAIT cell-deficient mice display impaired IL-7 production in the baseline thymus.

In order to identify the soluble factor produced by MAIT cells regulating IL-7 production, we first performed size exclusion purification. MAIT cells conditioned media were size-fractioned, and each fraction was used to stimulate TECs in vitro. Using this approach, we identified effector candidates >50 kDa in size. Using a dataset generated of MAIT cell-specific transcripts, we identified 7 molecules that (i) fell in this size range and (ii) are secreted and act as soluble factors. These included 2 factors that were in this size range in their active dimeric/trimeric forms. Based on these criteria, we could identify TNF superfamily member 14 (TNFSF14 or LIGHT) as a novel regulator of IL-7 production. Consistent with this putative role, gene expression silencing assays further identified LTbR as the main LIGHT receptor involved in this mechanism. Notably, we also found that MAIT cells could induce IL-7 in primary human bone marrow-derived mesenchymal cells, suggesting that this regulatory mechanism may be a broader phenomenon.

Here we show that the TNF superfamily member LIGHT can be a potent regulator of IL-7 production both in the thymus to assist in generation of new T cells, as well as in the periphery to maintain T cells. These finding therefore identify a novel regulator of IL-7 production and offer an innovative therapeutic target for improving T cell reconstitution after HCT.

Marco Rosichini: No relevant conflicts of interest to declare.